ABSENCE OF ACUTE COCAINE INTERACTIONS WITH THE MAO-B INHIBITOR SELEGILINE

被引:29
作者
HABERNY, KA
WALSH, SL
GINN, DH
WILKINS, JN
GARNER, JE
SETODA, D
BIGELOW, GE
机构
[1] JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BEHAV PHARMACOL RES UNIT,BALTIMORE,MD 21224
[2] VET ADM MED CTR 151L,DEPT PSYCHIAT,CLIN PSYCHOPHARMACOL UNIT,LOS ANGELES,CA 90073
[3] VET ADM MED CTR 151L,MEDICAT DEV UNIT,LOS ANGELES,CA 90073
关键词
SELEGILINE; L-DEPRENYL; COCAINE; SAFETY; CARDIOVASCULAR; SUBJECTIVE;
D O I
10.1016/0376-8716(95)01137-N
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Selegiline, an irreversible monoamine oxidase-B(MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measurable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 31 条
[1]   TURNOVER OF BRAIN MONOAMINE-OXIDASE MEASURED INVIVO BY POSITRON EMISSION TOMOGRAPHY USING L-[C-11]DEPRENYL [J].
ARNETT, CD ;
FOWLER, JS ;
MACGREGOR, RR ;
SCHLYER, DJ ;
WOLF, AP ;
LANGSTROM, B ;
HALLDIN, C .
JOURNAL OF NEUROCHEMISTRY, 1987, 49 (02) :522-527
[2]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[3]   NEW CONCEPTS IN COCAINE ADDICTION - THE DOPAMINE DEPLETION HYPOTHESIS [J].
DACKIS, CA ;
GOLD, MS .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1985, 9 (03) :469-477
[4]  
DACKIS CA, 1987, ARCH GEN PSYCHIAT, V44, P298
[5]   DEPRENYL ADMINISTRATION IN MAN - SELECTIVE MONO-AMINE OXIDASE-B INHIBITOR WITHOUT CHEESE EFFECT [J].
ELSWORTH, JD ;
GLOVER, V ;
REYNOLDS, GP ;
SANDLER, M ;
LEES, AJ ;
PHUAPRADIT, P ;
SHAW, KM ;
STERN, GM ;
KUMAR, P .
PSYCHOPHARMACOLOGY, 1978, 57 (01) :33-38
[6]  
FOLTIN RW, 1992, J PHARMACOL EXP THER, V261, P623
[7]   LONG-TERM EFFICACY AND SAFETY OF DEPRENYL (SELEGILINE) IN ADVANCED PARKINSONS-DISEASE [J].
GOLBE, LI .
NEUROLOGY, 1989, 39 (08) :1109-1111
[8]   COCAINE ABUSE TREATED WITH PHENELZINE [J].
GOLWYN, DH .
INTERNATIONAL JOURNAL OF THE ADDICTIONS, 1988, 23 (09) :897-905
[9]  
HITRI A, 1994, AM J PSYCHIAT, V151, P1074
[10]   EFFECTS OF REPEATED INJECTIONS OF COCAINE ON D1 AND D2 DOPAMINE-RECEPTORS IN RAT-BRAIN [J].
KLEVEN, MS ;
PERRY, BD ;
WOOLVERTON, WL ;
SEIDEN, LS .
BRAIN RESEARCH, 1990, 532 (1-2) :265-270